AllPeptides.eu - Advanced Peptide Research
    Back to BlogMetabolic Health & Diabetes

    What is Mazdutide? Dual GLP-1 and Glucagon Agonist

    AllPeptides.eu Editorial Team October 12, 2025 Updated: March 27, 2026 16 min read

    Summary

    Mazdutide is a weekly oxyntomodulin-based peptide that co-activates GLP-1 and glucagon receptors to reduce appetite and increase energy expenditure, achieving clinically significant weight loss in randomized trials. It received its first approvals in China in 2025.

    Substance Properties

    AliasesMazdutide · IBI‑362 · LY3305677
    Family / PathwayDual GLP‑1R / GCGR agonist (oxyntomodulin analogue)
    Molecular Weight~4,200 Da
    Half-life~5–6 days (weekly dosing)
    StorageRefrigerator 2–8 °C

    What is Mazdutide?

    Mazdutide (IBI-362 / LY3305677) is a weekly dual GLP-1 and glucagon receptor agonist, designed based on oxyntomodulin. In phase 2 and 3 studies, Mazdutide produced clinically significant weight loss along with improvements in multiple metabolic markers. China granted the first marketing approvals in 2025.

    Mechanism of action

    Acting simultaneously on GLP-1 and glucagon receptors, Mazdutide reduces appetite (GLP-1) while increasing energy expenditure (glucagon). This dual mechanism theoretically offers advantages over GLP-1 mono-agonists like semaglutide.

    Clinical results

    In randomized clinical trials in Chinese adults with overweight/obesity, Mazdutide achieved mean weight loss exceeding 10% at 24 weeks. Additionally, it improved glycemic control, blood lipids, and liver function markers.

    Comparison with Semaglutide and Tirzepatide

    While semaglutide (Ozempic/Wegovy) is a GLP-1 mono-agonist and tirzepatide (Mounjaro) is a dual GLP-1/GIP, Mazdutide targets GLP-1 and glucagon. The glucagon component theoretically increases energy metabolism, but head-to-head trials are needed for definitive comparisons.

    Frequently Asked Questions (FAQ)

    Is Mazdutide available?

    Mazdutide received marketing approvals in China in 2025. It is not yet approved in Europe or the US.

    What are the most common side effects?

    As with other GLP-1 agonists, gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common, particularly during dose escalation.

    References & Studies

    1. Ji L et al. Mazdutide for type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2023;11(8):562-573.

    Disclaimer

    This article is exclusively educational for researchers. It does not constitute medical advice.

    Educational contentRegularly reviewed & maintainedEvidence-based review
    Published: October 12, 2025 Updated: March 27, 2026 Author: AllPeptides.eu Editorial Team

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu